Ticagrelor versus Clopidogrel in the Dual Antiplatelet Regimen for Unruptured Intracranial Aneurysm Treated with Stent-Assisted Coil Embolization: A Single-Center Cohort Study

• Published in: World neurosurgery 2023-02, Vol.170, p.e755-e765
• Main Authors: Yi, Man-Man, Do, Hong Phuoc, Li, Yi-Chen, Wang, Rong, Zhuang, Zong, Xu, Man-Man, Liu, Tao, Shao, Teng-Fei, Ding, Lan-Ping, Ge, Wei-Hong
• Format: Article
• Language: English
• Subjects: Adenosine Diphosphate; Antiplatelet agent; Clopidogrel; Clopidogrel - therapeutic use; Cohort Studies; Embolization, Therapeutic; Fibrinogen - therapeutic use; Humans; Intracranial Aneurysm - drug therapy; Intracranial aneurysms; Platelet Aggregation Inhibitors - therapeutic use; Stent-assisted coiling; Stents; Ticagrelor; Ticagrelor - therapeutic use; Treatment Outcome
• ISSN: 1878-8750; 1878-8769; 1878-8769
• DOI: 10.1016/j.wneu.2022.11.102

Dual antiplatelet therapy (DAPT) of aspirin plus clopidogrel is commonly used in patients with unruptured intracranial aneurysms treated with stent-assisted coil (SAC) embolization. However, the unpredictable clopidogrel efficacy of the 5%–55% nonresponders limits its use. Ticagrelor, as a potential alternative of clopidogrel, is an antiplatelet agent with low resistance rates but uncertain efficacy and safety in these patients. A single-center cohort study was performed to compare the efficacy and safety of ticagrelor with clopidogrel in the DAPT regimen in patients with unruptured intracranial aneurysms and treated with SAC. The patients with clopidogrel resistance identified as inadequate adenosine diphosphate inhibition rate determined by thromboelastography were treated with ticagrelor instead, and both drugs achieved adequate suppression of platelet aggregation when stents were implanted. The occurrence of major adverse cardiovascular and cerebrovascular events (MACCE) and bleeding events was recorded through 6 months follow-up. Data from 86 patients with 99 unruptured intracranial aneurysms and treated by SAC with clopidogrel were compared with those from 108 patients with 111 aneurysms and treated with ticagrelor. Neither the baseline characteristics nor the incidence of the MACCE or bleeding events differed between the groups. Ticagrelor exerted significantly higher adenosine diphosphate inhibition rate than that of the clopidogrel. Multivariable logistic regression analysis showed that the incidence of MACCE was related to hematocrit and fibrinogen levels. Ticagrelor seemed to be as effective and safe as clopidogrel for SAC in unruptured intracranial aneurysms. Hematocrit and fibrinogen levels were independent risk factors for the incidence of MACCE.